The Department of Medicine
Jonathan S. Wall, PhD
Professor and Assistant Dean for Research
Division of Research
Preclinical and Diagnostic Molecular Imaging Laboratory
https://orcid.org/0000-0002-5516-8578
Research Focus
Dr. Wall is a tenured Professor at the University of Tennessee Graduate School of Medicine where he directs the NIH-funded Amyloidosis and Cancer Theranostics Program focused on the development and translation of biologicals for imaging and therapy of systemic amyloid diseases. Amyloidosis is a family of diseases of increasing recognition, impacting older adults. The amyloid "complex" comprised of clumps of abnormal protein fragments can infiltrate many organs including the heart, nerves and brain. Dr. Wall has over 100 publications, ~13 issued US patents, and has garnered over $10M in grants and research contracts. He and his team have recently started, at UTMC, a new investigator-initiated Phase 1 "first-in-man" clinical trial of a promising new imaging agent for the detection of systemic amyloidosis and they are working to develop novel therapeutic strategies that may help to remove the amyloid complex from the body.
Education
Postdoctoral
University of Tennessee Medical Center
Human Immunology & Cancer Program
Knoxville, TN (January 1995- April 1997)
Graduate
University of Essex
Department of Chemistry & Biological Chemistry, Colchester, UK (October 1991- December 1994).
Ph.D conferred July 1995
Undergraduate
University of Essex
Department of Biology
Colchester, UK (October 1987-June 1991).
BSc. (Hons.) Biological Sciences, July 1991
Faculty Appointments
Professor, University of Tennessee Graduate School of Medicine, Knoxville, TN (June 2009 - present)
Associate Professor, University of Tennessee Graduate School of Medicine, Knoxville, TN (June 2003 - June 2009)
Assistant Professor, University of Tennessee Graduate School of Medicine, Knoxville, TN (April 1997 - June 2003)
Adjunct Associate Professor, Department of Small Animal Clinical Sciences, University of Tennessee, College of Veterinary Medicine, Knoxville, TN (July 2007 - present)
Director, Preclinical and Diagnostic Molecular Imaging Laboratory, University of Tennessee Graduate School of Medicine, Knoxville, TN (11/2005 - present)
Awards and Honors
2011 World Molecular Imaging Congress
San Diego, California
Inveon Image of the Year Award 2011
Translational Image of the Year Award 2011
GSM Faculty Award 2011
GSM Spirit Award
University of Tennessee Graduate School of Medicine, June 2011
Visiting Professor
Amyloid, melanoma and the missing molecular link
University of Uppsala,
Uppsala, Sweden, April 7th 2011
Visiting Professor
Animal imaging in basic, clinical, and translational research
Biochemistry and Molecular Biology Seminar Series,
The Mayo Clinic,
Rochester, MN. March 1st 2011
2010 World Molecular Imaging Congress
Kyoto, Japan
Inveon Image of the Year 2010
Best Presented Image of the Year 2010
Memberships
Member of the American Association of Immunologists (2001-present)
Society of Nuclear Medicine (May 2007-present)
American Association for Laboratory Animal Science (Gold Membership; 2007- present)
International Society of Amyloidosis (Jan 2008- present)
Honorary member Phi Zeta - The Honor Society of Veterinary Medicine (April 2008-present)
Current Publications
Dorbala S, Adigun R, Alexander KM, Brambatti M, Cuddy SAM, Dispenzieri A, Dunnmon P, Emdin M, Abou Ezzeddine OF, Falk RH, Fontana M, Grodin JL, Guthrie S, Jerosch-Herold M, Hofling AA, Hsu K, Lin G, Masri A, Maurer MS, Mittmann C, et-al.
Development of imaging endpoints for clinical trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum. JACC Cardiovasc Imaging. 2025 Feb 20:S1936-878X(25)00023-3. doi: 10.1016/j.jcmg.2024.11.003. Online ahead of print.
Hancock TJ, Vlasyuk M, Foster JS, Macy S, Wooliver DC, Balachandran M, Williams AD, Martin EB, Kennel SJ, Heidel ER, Wall JS, Jackson JW..
Neutrophils enhance the clearance of systemic amyloid deposits in a murine amyloidoma model. Front Immunol. 2024 Nov 12;15:1487250. doi: 10.3389/fimmu.2024.1487250. eCollection 2024.
Wall JS, Kennel SJ, Stuckey A,Whittle B, Jackson JW, Williams AD, Hancock T, R. Heidel R, Mehmood M, Kassira A, Lands RH, Watson H, Hung R, Martin EB.
Preliminary observations using 99m-Tc-peptide P5+14 for the detection of AL amyloidosis using SPECT/CT and planar gamma scintigraphic imaging. Blood. 2024,Volume 144, Supplement 1,Page 1910,ISSN 0006-4971,https://doi.org/10.1182/blood-2024-207978.
Wall JS, Kennel SJ, Stuckey A, Richey T, Williams AD, Balachandran M, Hancock T, Jackson JW, Wooliver DC, Macy S, Heidel ER, Lands RH, Martin EB.
Characterization of AT02 bioactivity and an assessment of its potential use as an amyloid-clearing therapeutic for AL amyloidosis. Blood. 2024,Volume 144, Supplement 1,,Page 4641,ISSN 0006-4971, https://doi.org/10.1182/blood-2024-208282.
Martin EB, Stuckey A, Heidel ER, Whittle B, Kassira A, Lands R, Watson H, Raj R, Powell D, Kennel S, Wall JS.
Amyloid imaging with 124I-evuzamitide can detect temporal changes in systemic amyloid load and correlates with echocardiographic parameters in patients with AL or ATTR amyloidosis. Journal of Nuclear Cardiology. 2024,Volume 38, Supplement,101938,ISSN 1071-3581,https://doi.org/10.1016/j.nuclcard.2024.101938.
Heidel ER, Stuckey A, Martin EB, Weisman A, Whittle B, Kennel S, Wall JS.
Differentiation of ATTR amyloidosis based on abdominothoracic organ uptake of 124I-evuzamitide assessed by PET/CT imaging. Journal of Nuclear Cardiology. 2024,Volume 38, Supplement,101939,ISSN 1071-3581,https://doi.org/10.1016/j.nuclcard.2024.101939
Wall J, Martin E, Stuckey A, Whittle B, Jackson J, Williams A, Hancock T, Heidel ER, Mehmood M, Kassira A, Lands R, Watson H, Hung R, Kennel S.
Preliminary evaluation of 99mTc-labeled peptide P5+14 for the detection of cardiopulmonary amyloidosis using SPECT/CT and planar gamma scintigraphic imaging. Journal of Nuclear Medicine. Jun 2024, 65 (supplement 2) 241277
Wall JS, Martin EB, Stuckey A, Whittle B, Jackson JW, Williams A,Hancock T, Heidel ER, Mehmood M, Kassira A, Watson H, Hung R, Kennel S.
Early evaluation of 99mTc-labeled peptide P5+14 for the detection of cardiac amyloidosis using SPECT/CT and planar gamma scintigraphic imaging. Journal of Nuclear Cardiology. 2024,Volume 38, Supplement,102002,ISSN 1071-3581,https://doi.org/10.1016/j.nuclcard.2024.102002.
Lands R, Martin EB, Powell D, Stuckey A, Whittle B, Guthrie S, Raj R, Kennel SJ, Wall JS.
Longitudinal PET/CT imaging with iodine ((124)i) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis. Amyloid. 2024 Jun;31(2):148-149. doi: 10.1080/13506129.2023.2286427. Epub 2023 Nov 22.
Kennel SJ, Jackson JW, Stuckey A, Richey T, Foster JS, Wall JS.
Preclinical evaluation of Tc-99m p5+14 peptide for spect detection of cardiac amyloidosis. PLoS One. 2024 Apr 5;19(4):e0301756. doi: 10.1371/journal.pone.0301756. eCollection 2024.
Wall J, Martin E , Heidel R, Stuckey A, Whittle B, Jackson J, Williams A, Mehmood M, Kanderian A, Rebecca K, Hung R, Lands R, Kennel S.
Detection of amyloid cardiomyopathy in patients with systemic ATTR and AL amyloidosis using SPECT/CT and planar imaging of a technetium-99m-labeled peptide - technetium-99m (99mTc) evuzamitide. Journal of the American College of Cardiology . 2024 Apr, 83 (13_Supplement) 1369.https://doi.org/10.1016/S0735-1097(24)03359-X
Martin E, Stuckey A, Heidel E, Kennel S, Guthrie S, Wall J.
Repeat imaging of patients with AL and ATTR amyloidosis, by 124I-AT-01 PET/CT imaging, reveals dynamic organ-specific changes in amyloid load over time. Journal of Cardiac Failure. 2024, Volume 30, Issue 1,Page 200,ISSN 1071-9164,https://doi.org/10.1016/j.cardfail.2023.10.202.
Wall JS, Martin EB, Lands R, Ramchandren R, Stuckey A, Heidel RE, Whittle B, Powell D, Richey T, Williams AD, Foster JS, Guthrie S, Kennel SJ.
Cardiac amyloid detection by PET/CT imaging of iodine ((124)i) evuzamitide ((124)i-p5+14): A phase 1/2 study. JACC Cardiovasc Imaging. 2023 Nov;16(11):1433-1448. doi: 10.1016/j.jcmg.2023.08.009.
Foster JS, Balachandran M, Hancock TJ, Martin EB, Macy S, Wooliver C, Richey T, Stuckey A, Williams AD, Jackson JW, Kennel SJ, Wall JS.
Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion. Front Immunol. 2023 Oct 2;14:1275372. doi: 10.3389/fimmu.2023.1275372. eCollection 2023.
Jackson JW, Foster JS, Martin EB, Macy S, Wooliver C, Balachandran M, Richey T, Heidel RE, Williams AD, Kennel SJ, Wall JS.
Collagen inhibits phagocytosis of amyloid in vitro and in vivo and may act as a 'don't eat me' signal. Amyloid. 2023 Sep;30(3):249-260. doi: 10.1080/13506129.2022.2155133. Epub 2022 Dec 21.
Smiley D, Einstein AJ, Chan N, Mintz A, Santana DD, Shetty M, Sekulic M, Goldner K, Wall J, Helmke S, Maurer MS.
Smitcardiac amyloidosis identified by (124)I-AT-01 PET imaging but not cardiac MRI or SPECT (99m)Tc pyrophosphate scintigraphy. J Nucl Cardiol. 2023 May 3. doi: 10.1007/s12350-023-03267-7. Online ahead of print.
Martin EB, Stuckey A, Powell D, Lands R, Whittle B, Wooliver C, Macy S, Foster JS, Guthrie S, Kennel SJ, Wall JS.
Clinical confirmation of pan-amyloid reactivity of radioiodinated peptide (124)I-p5+14 (AT-01) in patients with diverse types of systemic amyloidosis demonstrated by PET/CT imaging. Pharmaceuticals (Basel). 2023 Apr 21;16(4):629. doi: 10.3390/ph16040629.
Wall JS, Martin EB, Endsley A, Stuckey AC, Williams AD, Powell D, Whittle B, Hall S, Lambeth TR, Julian RR, Stabin M, Lands RH, Kennel SJ.
First in human evaluation and dosimetry calculations for peptide (124)I-p5+14-a novel radiotracer for the detection of systemic amyloidosis using PET/CT imaging. Mol Imaging Biol. 2022 Jun;24(3):479-488. doi: 10.1007/s11307-021-01681-2. Epub 2021 Nov 16.